Wendy future of retail top

Pfizer says its experimental COVID-19 pill reduces risk of hospitalization, death

Print Friendly, PDF & Email

NEW YORK — Pfizer’s new experimental antiviral pill to treat COVID-19 cut by 89% the chance of hospitalization or death for adults at risk of severe disease, the company reported on Friday, as its CEO Albert Bourla promised to make it a new weapon in the battle against the pandemic available globally as quickly as possible.

The trial’s results suggest that Pfizer’s drug surpasses Merck & Co pill, molnupiravir, which was shown last month to halve the chance of dying or being hospitalized for COVID-19 patients at high risk of serious illness.

Pfizer’s pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year. Pfizer said it plans to submit interim trial results to the Food and Drug Administration (FDA) before the Nov. 25 U.S. Thanksgiving holiday. The trial was stopped early due to its high success rate.


ECRM_06-01-22


Comments are closed.

PP_1170x120_10-25-21